Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Oct 15th, 3:29 PM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | N/A - N/A |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
BioMedNewsBreaks — Adageis CEO Discusses AI-Driven Solutions for Value-Based Care in Latest Bell2Bell Podcast
Adageis, a healthcare technology company revolutionizing patient care through innovative digital solutions, is featured in the latest episode of The Bell2Bell Podcast, produced by IBN, a multifaceted communications organization connecting public companies with the investment community. In the interview, Adageis CEO Shane Speirs explains how the company’s AI-powered platform simplifies the administrative challenges of delivering value-based care by digitizing complex insurance and compliance processes. “We make it easy to see what measures practices need to hit and how to hit them for each individual patient,” Speirs said, noting that Adageis currently supports more than 580,000 patient lives. The conversation explores Adageis’ scalable per-provider model, rapid growth, and mission to make value-based care accessible to all providers.
Via Investor Brand Network · October 15, 2025
On October 14, 2025, Tesla (NASDAQ: TSLA) is not just making headlines in the automotive world, but also as a formidable force and a top stock mover in the energy sector. The company's relentless innovation and strategic expansion in energy storage and charging infrastructure are reshaping the global transition to
Via MarketMinute · October 14, 2025
The American automotive market witnessed an unprecedented milestone in September 2025, as the average price of a new vehicle in the U.S. surged to a record-high of $50,080. This marks the first time new car prices have crossed the $50,000 threshold, a significant leap driven primarily by
Via MarketMinute · October 14, 2025
Ferrari Stock Trots Back Up Premarket After Worst Day Ever: Retail Bulls Hold Their Convictionstocktwits.com
Via Stocktwits · October 10, 2025
A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency across critical industries. This new AI tool has made checking the quality of materials significantly easier, with profound and immediate implications for sectors such
Via MarketMinute · October 14, 2025
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Completes Phase 1a Trial of TTX-MC138, Advancing to Phase 2 Evaluation
TransCode Therapeutics (NASDAQ: RNAZ) announced completion of its Phase 1a clinical trial of TTX-MC138, an investigational inhibitor of microRNA-10b, achieving its primary safety endpoint and establishing a recommended Phase 2 dose. Sixteen patients were treated with no significant safety events or dose-limiting toxicities observed, and 44% achieved stable disease lasting four months or longer. The favorable safety, durability, and pharmacodynamic data support advancing TTX-MC138 into a Phase 2a trial to further assess efficacy across multiple metastatic cancer indications.
Via Investor Brand Network · October 14, 2025
BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Appoints Amanda L. Ferrio as Chief Financial Officer
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels, announced the promotion of Amanda L. Ferrio to Chief Financial Officer, succeeding Cecile Munnik, CPA/CA, following a transition period through the company’s Q3 2025 filing. Ferrio, who has over 15 years of accounting and finance experience, previously served as Vice President of Accounting & Finance at Progressive Care LLC, where she led financial reporting, budgeting, and SEC compliance. CEO David Phipps said her deep operational insight will support NextPlat’s focus on financial performance and sustainable shareholder value.
Via Investor Brand Network · October 14, 2025
New Report Highlights Concerning Trends in the US Health Care System
There is general agreement that the U.S. health care system has issues, but there isn’t consensus on what exactly needs to be done to fix those issues. A new report published by Trilliant Health, an economic analysis company, points out some notable trends that should be given the attention they deserve by health care system stakeholders.
Via Investor Brand Network · October 14, 2025
Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026
Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline ( https://ibn.fm/tCsub ). This funding extends Soligenix’s cash runway through the end of 2026, ensuring that the company has the financial resources to reach key inflection points across its portfolio, including late-stage clinical trials and regulatory milestones. The move underscores Soligenix’s commitment to advancing therapies for rare diseases where there is significant unmet medical need.
Via Investor Brand Network · October 13, 2025
Derrimut VIC () October 12, 2025 -- The leading motorcycle dismantling service launches worldwide shipping while expanding domestic operations to meet rising demand for quality used parts.
Via Prodigy · October 12, 2025
Frankfurt, Germany – October 10, 2025 – European financial markets closed sharply lower today, October 10, 2025, as a sudden and aggressive escalation in the US-China trade dispute sent shockwaves across the continent. Major indices plummeted, and a broad sell-off of equities underscored investor anxieties about global economic stability. The renewed tensions,
Via MarketMinute · October 10, 2025
In a landmark move poised to redefine the application of artificial intelligence, CoreWeave, a specialized provider of high-performance cloud infrastructure, announced its agreement to acquire Monolith AI. The acquisition, unveiled around October 6, 2025, marks a pivotal moment, signaling CoreWeave's aggressive expansion beyond traditional AI workloads into the intricate world of industrial design and complex [...]
Via TokenRing AI · October 10, 2025
How You Can Support Your Loved One Undergoing Cancer Treatment
Having a loved one diagnosed with cancer can be a very difficult time for that person and those within their immediate circle. It is often difficult to know how to support the patient during their treatment and some people make mistakes in their bid to be supportive. We discuss some suggestions that could be helpful if a loved one is undergoing cancer treatment.
Via Investor Brand Network · October 10, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Partners with Brand Institute to Develop Global Brand Identity for AVERSA FENTANYL
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced that its subsidiary 4P Therapeutics has signed an agreement with Brand Institute, Inc., a global leader in pharmaceutical brand name and identity development, to create the worldwide commercial brand name and visual identity for AVERSA FENTANYL, the company’s lead product utilizing its AVERSA(TM) abuse-deterrent transdermal technology. Designed to deter misuse and reduce accidental opioid exposure, AVERSA FENTANYL could become the world’s first abuse-deterrent opioid patch. Brand Institute, with a 75% share of global drug name approvals and 87% of FDA-approved names in 2024, will lead the initiative alongside its regulatory subsidiary, Drug Safety Institute, which is staffed by former FDA, EMA, Health Canada, USAN, and WHO officials.
Via Investor Brand Network · October 10, 2025
Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL
Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people ( https://ibn.fm/ANk8X ). Despite its rarity, CTCL presents a substantial unmet medical need, particularly in early-stage patients who often have limited treatment options. Addressing this gap, Soligenix (NASDAQ: SNGX) recently announced the expansion of its European Medical Advisory Board (“MAB”) ( https://ibn.fm/6354Y ) to provide additional clinical and strategic guidance as the company advances its confirmatory phase 3 study (referred to as FLASH2) evaluating the safety and efficacy of its proprietary CTCL treatment: HyBryte(TM).
Via Investor Brand Network · October 9, 2025
In a groundbreaking collaboration, researchers from the Massachusetts Institute of Technology (MIT) and the Toyota Research Institute (TRI) have unveiled a revolutionary AI tool designed to create vast, realistic, and diverse virtual environments for robot training. This innovative system, dubbed "Steerable Scene Generation," promises to dramatically accelerate the development of more intelligent and adaptable robots, [...]
Via TokenRing AI · October 9, 2025
Scientists Stunned Upon Discovering Glioblastoma Erodes Skull Tissue
For long, treatment approaches to glioblastoma, the deadliest form of brain cancer, have assumed that the disease is localized. However, a recent study has found that GBM erodes the skulls of its victims and this could partially explain why the current therapies have had dismal success rates against the tumors.
Via Investor Brand Network · October 9, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports Biomarker Data Showing Buntanetap Reduces Inflammation and Strengthens Neuronal Health in Alzheimer’s Patients
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced new results showing that buntanetap reduced key inflammatory biomarkers and improved neuronal integrity in Alzheimer’s patients. Data from the Phase 2/3 study demonstrated lower levels of IL-5, IL-6, S100A12, IFN-γ, and IGF1R in treated patients versus placebo, along with reduced neurofilament light chain (NFL), suggesting improved cellular health and potential disease-modifying effects. CEO Maria Maccechini said the findings confirm buntanetap’s multi-targeted mechanism and validate earlier preclinical and clinical results, advancing confidence in its potential to deliver meaningful therapeutic benefit.
Via Investor Brand Network · October 9, 2025
European stock markets are experiencing a remarkable surge, with key indices reaching unprecedented levels as of October 8, 2025. This robust performance is signaling a significant shift in investor sentiment towards the continent's equities, driven by a confluence of factors ranging from anticipated monetary easing by central banks to a
Via MarketMinute · October 8, 2025
Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a leading medical device firm in the field of breast cancer imaging solutions, is speeding up its efforts towards commercializing its innovations. Izotropic recently made public significant progress in its IzoView Breast CT system, a feature designed to give patients a customized radiation dose ideal for their composition and breast sizes ( ibn.fm/N83Cp ).
Via Investor Brand Network · October 8, 2025
Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company advancing a diversified pipeline spanning oncology, immunotherapy, neurodegeneration, and rare diseases. In a recent interview on the BioMedWire podcast, Chairman and CEO Dr. Vuong Trieu emphasized the company’s unique model: focusing on de-risked, late-stage assets and accelerating their development through regulatory pathways designed for speed and efficiency.
Via Investor Brand Network · October 8, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Nutriband (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Wednesday, Oct. 8, 2025, at 3 p.m. ET. The presentation will include a fireside Q&A session with questions from the live virtual audience, and registered investors can also schedule one-on-one meetings with Melnik. Interested attendees can register at no cost via the conference’s official site. A video webcast of the presentation will be available on Channelchek, Noble’s investor portal, and archived for 90 days on both Channelchek.com and Nutriband’s website.
Via Investor Brand Network · October 8, 2025
Denver, CO – October 7, 2025 – Solid Power, Inc. (NASDAQ: SLDP), a leading developer of all-solid-state battery technology, has reached a new 52-week high today, with its stock trading as high as $6.30 and closing at $6.33. This significant milestone underscores growing investor confidence in the company's groundbreaking advancements
Via MarketMinute · October 7, 2025
Munich, Germany – October 7, 2025 – Luxury automotive giant Bayerische Motoren Werke AG (BWM.DE) (BMWYY) has delivered a sobering outlook for the coming year, announcing a significant cut to its 2025 earnings forecast. The revised projections, revealed today, paint a picture of increased caution, primarily driven by a protracted slowdown
Via MarketMinute · October 7, 2025
Louisville, CO – October 7, 2025 – Solid Power (NASDAQ: SLDP), a leading developer of all-solid-state battery technology, has reached an impressive new 52-week high, with shares trading as high as $6.30 today. This significant surge in stock price reflects growing investor confidence and market optimism surrounding the company's continuous advancements
Via MarketMinute · October 7, 2025